Overview

Phase I BLASST-3 Trial

Status:
Not yet recruiting

Trial end date:
2023-01-25

Target enrollment:

Participant gender:

Summary

The aim of this research is to see whether using a drug that blocks a protein called FGFR (fibroblast growth factor receptor) prior to surgery is safe and effective in patients with bladder cancer that have mutations in FGFR3 or FGFR2 and who cannot receive chemotherapy with cisplatin prior to surgery The name of the study drug involved in this study is: - Infigratinib

Phase:

Phase 1

Details

Lead Sponsor:

Guru P. Sonpavde

Collaborator:

QED Therapeutics, Inc.

Treatments:

Infigratinib